LONDON, UK / ACCESS Newswire / September 19, 2025 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK 2. ...

Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced the submission of its full pre-submission (Pre-Sub) package to the U.S. Food and Drug Administration (FDA) for its PL-14 product, designed to help individuals suffering from nasal allergies. The submission includes comprehensive documentation covering manufacturing plans, clinical development strategies, ...

公司战略调整 - 公司正式撤回反向股票分割提案 经过审慎考虑后决定停止该计划[1][2] - 管理层承诺通过多渠道与股东保持频繁沟通 强调专注于口服疫苗平台科学进展以创造长期股东价值[2] 业务与技术优势 - 公司专注于临床阶段口服重组疫苗研发 拥有专有递送平台技术 疫苗采用药丸形式无需冷藏储存和运输且无针刺损伤风险[3] - 技术平台适用于多种重组疫苗开发 包括现有疫苗口服版本和新适应症重组疫苗 当前研发管线涵盖冠状病毒、诺如病毒、流感预防性疫苗及HPV治疗性肿瘤免疫疫苗[3] - 已在全球提交多项专利保护 覆盖使用腺病毒和TLR3激动剂的口服疫苗接种技术[3] 企业基本信息 - 公司为临床阶段生物技术企业 股票代码OTCQX: VXRT 总部位于美国加州南旧金山[1][3] - 媒体与投资者关系由FINN Partners机构代理 指定联系人为Matt Steinberg[5]

U.S. stock index futures are showing a mixed performance this Friday morning, September 19, 2025, as investors digest a recent Federal Reserve interest rate cut and look ahead to upcoming economic data. After major indexes closed at record highs on Thursday, premarket trading suggests a cautious start to the day, with S&P 500 (SPX), Nasdaq 100 (US100:IND), and Dow Jones Industrial Average (INDU) futures experiencing slight fluctuations. This follows a period of robust gains driven by optimism surrounding mo ...

REDWOOD CITY, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced today the pricing of its underwritten public offering of (i) an aggregate of 11,670,707 shares of its common stock and accompanying commo ...

How many speculative stocks can you own this year. We've seen fortunes made in speculative stocks. And by speculative, I mean companies that don't turn a profit or maybe they have some earnings, but you're paying a ridiculous mold for them.I've wrestled mightily with this particular question from my chapel trust. I spoke a bit about it in today's investing club meeting. The answer might surprise you.I am actually all in favor of speculation, but it's got to be done wisely. In fact, if you're younger, I actu ...

Key Points A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. 10 stocks we like better than Replimune Group › On Thursday, Replimune (NASDAQ: REPL) had a crucial meeting with federal regulators regarding one of its leading drug candidates. While the outcome of the event wasn't necessarily negative, it left the future of the drug up in the air, and investors didn't like that uncertainty. As a result, they assertively traded ...

In trading on Thursday, shares of Dyne Therapeutics Inc (Symbol: DYN) crossed above their 200 day moving average of $13.82, changing hands as high as $13.98 per share. Dyne Therapeutics Inc shares are currently trading up about 5.9% on the day. The chart below shows the one year performance of DYN shares, versus its 200 day moving average:Looking at the chart above, DYN's low point in its 52 week range is $6.36 per share, with $37.08 as the 52 week high point — that compares with a last trade of $13.92. C ...

REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced today that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of its common ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?I have given Novavax, Inc. (NASDAQ: NVAX ) stock three straight Sell recommendations in my last three articles on the Gaithersburg, Maryland-based vaccine maker, in October 2024 , February this year , and mostThe g ...